The trial can't be that bad if it can treat cancer, although not...

The trial can't be that bad if it can treat cancer, although not cure it.

Article below:

Sirtex Cancer Treatment Still Holds Promise, UBS Says -- Market Talk

SRX21.253.72 (21.22%)ASX real-time quotes as of 18 03 2015 02:33pm AEDT

• Dow Jones
• 18 03 2015 10:06am AEDT
  
  2306 GMT [Dow Jones] Sirtex Medical Ltd.'s (SRX.AU) mixed results from a key clinical trial of its Sirflox cancer treatment is a significant disappointment but there remains an opportunity for the Australian company to tap a larger market, UBS reckons. The trial failed to meet its primary target as a treatment for metastatic colorectal cancer but still showed a promising result in controlling cancer in the liver. That suggests the treatment will find a bigger market than currently given the opportunity to treat the liver as part of a broader regime to address the wider metastasis of cancer throughout the body, the brokerage says. It retains a buy recommendation despite expecting the stock to reflect investor doubts into the medium term, and cuts its price target to 28.75 Australian dollars/share ($21.97/share) from A$50.40. SRX last traded at A$17.53. ([email protected]; @RobbMStewart)
  
  (END) Dow Jones Newswires
  March 17, 2015 19:06 ET (23:06 GMT)
  Copyright (c) 2015 Dow Jones & Company, Inc.

,